Seroprevalence of Hepatitis A Virus in Patients with Chronic Hepatitis B or C in Isfahan Province, Iran

A number of researchers have suggested that the clinical course of hepatitis A virus (HAV) infection is more severe in patients with chronic liver disease (CLD). However, there is not adequate information about the seroprevalence and risk factors of HAV in the population with chronic hepatitis B or C infection in Isfahan, Iran. We studied 168 patients with chronic hepatitis B or C between spring 2007 and spring 2009. Patients were stratified based on age, gender, family size, intravenous drug abuse, education, and genotype of hepatitis C. Independent predictors of HAV were identified by logistic regression analysis. Of 168 patients, 162 persons (96.4%) were HAV seropositive. We found a significant relation between genotypes of hepatitis C and HAV seropositivity (P < 0.001). Other risk factors were not identified as independent predictors. Considering the high seroprevalence of HAV in patients with hepatitis B or hepatitis C, general vaccination against HAV is not necessary. Further studies should be conducted to draw a firm decision on vaccination of seronegative patients.